Metraipolis › archive › dc_1f9cfb8fd5bc
Prevalence and features of allergic bronchopulmonary aspergillosis, United States, 2016-2022 — Europe PMC PMID:39813272
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/39813272
- DOI
- 10.1371/journal.pone.0317054
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T13:46:42.903Z
- SHA-256 of the archived text
1cfd5a898badec01ef8817e45b00b40310fb2cce622df6731bbbfd9a105120bc- Stable URL of this page
https://metraipolis.com/documento/dc_1f9cfb8fd5bc
How to cite
Prevalence and features of allergic bronchopulmonary aspergillosis, United States, 2016-2022 — Europe PMC PMID:39813272 — Europe PMC (en), https://europepmc.org/article/MED/39813272 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_1f9cfb8fd5bc (Metraipolis archive dc_1f9cfb8fd5bc, sha256 1cfd5a898badec01ef8817e45b00b40310fb2cce622df6731bbbfd9a105120bc)
BibTeX
@misc{dc1f9cfb8fd5bc,
title = {Prevalence and features of allergic bronchopulmonary aspergillosis, United States, 2016-2022 — Europe PMC PMID:39813272},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/39813272},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_1f9cfb8fd5bc; sha256 1cfd5a898badec01ef8817e45b00b40310fb2cce622df6731bbbfd9a105120bc},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/39813272. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
The epidemiology of allergic bronchopulmonary aspergillosis (ABPA) in the United States is not well-described. To estimate national ABPA prevalence among patients with asthma or cystic fibrosis, characterize ABPA testing practices, and describe ABPA clinical features, treatment, and 6-month outcomes. We used the 2016-2022 Merative™ MarketScan® Commercial/Medicare and Multi-State Medicaid Databases to identify cohorts of patients with 1) asthma, 2) cystic fibrosis (CF), and 3) ABPA. We calculated ABPA prevalence per 10,000 patients with asthma or CF, assessed diagnostic testing for ABPA among patients with severe asthma, and described features of patients with ABPA using diagnosis and procedure codes. The overall ABPA prevalence among patients with asthma was 2.8/10,000 (Commercial/Medicare) and 1.0/10,000 (Medicaid). ABPA prevalence increased with asthma severity (Commercial/Medicare: mild 1.3, moderate 9.3, severe 70.6, Medicaid: mild 0.3, moderate 2.4, severe 32.4). Among patients with CF, ABPA prevalence was 183.7/10,000 (Commercial/Medicare) and 134.6/10,000 (Medicaid). Among patients with severe asthma, 10.3% (Commercial/Medicare) and 7.4% (Medicaid) received total immunoglobulin E testing, which is recommended for ABPA diagnosis. Among all patients with ABPA (Commercial/Medicare: n = 1,564, Medicaid: n = 410), ABPA treatments included inhaled corticosteroids (>70%), systemic corticosteroids (>62%), and antifungals (>18%). Patients with ABPA and Medicaid were more likely to experience hospitalization (45.1% vs. 22.5% of patients with Commercial/Medicare insurance) and respiratory failure (18.5% vs. 10.9%). This analysis provides initial estimates of national ABPA prevalence. Further studies could identify potential barriers to ABPA testing and investigate potential factors affecting payer-related differences in ABPA burden. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2025 (prima pubblicazione 2025-01-15). Identificativi: PMID 39813272 · PMCID PMC11734977 · DOI 10.1371/journal.pone.0317054. Descrittori MeSH principali: Aspergillosis, Allergic Bronchopulmonary. Pagina: https://europepmc.org/article/MED/39813272 — https://doi.org/10.1371/journal.pone.0317054. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T12:00:49.548Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.